IntegraGen reports 2019 annual results

integragen

+20% sales growth, positive gross operating surplus during second half of year, and close to break-even for the year

IntegraGen announced its financial results for the year ending December 31, 2019. The annual accounts were approved by the Board of Directors at a meeting held on April 2, 2020.

Operating (…)  » 

IntegraGen announces leading U.S. cancer center to use MERCURY™ cloud-based tool for oncology sequencing data interpretation and reporting

IntegraGen today announced Dana-Farber Cancer Institute will utilize the company’s MERCURY™ cloud-based software as part of their analysis and reporting process for sequencing data obtained from tumors of cancer patients. Dana-Farber plans to utilize MERCURY to assist in the analysis of sequencing data obtained from small and large (…)  » 

Press release on General Assembly voting results

integragen

The mixed shareholders’ general meeting of IntegraGen was held on Thursday, June 13, 2019 at the Bedford Hotel’s premises at 17 rue de l’Arcade in Paris.

At the end of the Combined General Meeting, (…)  » 

IntegraGen Reports 2018 Annual Results

integragen

IntegraGen has announced the company’s financial results for the year ending December 31, 2018. The annual accounts were approved by the Board of Directors held on April 17, 2019.

Click here to view press release.

 

 

IntegraGen and Advanced Biological Laboratories sign global licensing agreement for the commercialization of miRpredX test

IntegraGen and Advanced Biological Laboratories (ABL) have announced the signing of a non-exclusive global licensing agreement enabling ABL to distribute miRpredX™, IntegraGen’s proprietary IVD CE marked  diagnostic test that enables clinicians to identify metastatic colorectal cancer patients who have a higher likelihood of response to anti-EGFR therapy.

(…)  »